Subtype
Supratentorial Neoplasm
CI-CAN-00006859Explore in graph →
Non-malignant33 active trials19 evidence items
Loading cancer entity…
Subtype
CI-CAN-00006859Explore in graph →
Clinical trials
144 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | terminated | Phase 2 | 84 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02758366 |
| Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma |
| terminated |
| Phase 2 |
| 21 |
| Meyer Children's Hospital IRCCSOTHER |
| 1 |
| Feb 9, 2021 |
| clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials